OPKO Health Sees Unusually High Options Volume (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK) was the recipient of unusually large options trading on Monday. Investors bought 9,645 call options on the company. This represents an increase of approximately 402% compared to the typical volume of 1,921 call options.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 150,000 shares of the company’s stock in a transaction dated Friday, January 17th. The stock was purchased at an average price of $1.47 per share, for a total transaction of $220,500.00. Following the acquisition, the chief executive officer now owns 213,186,477 shares in the company, valued at $313,384,121.19. This trade represents a 0.07 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders purchased 1,521,609 shares of company stock worth $2,313,710. 47.26% of the stock is currently owned by company insiders.

Institutional Trading of OPKO Health

Several large investors have recently added to or reduced their stakes in OPK. Rubric Capital Management LP grew its stake in OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares during the last quarter. Millennium Management LLC grew its stake in OPKO Health by 85.3% during the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Lazard Asset Management LLC grew its stake in OPKO Health by 143.6% during the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after purchasing an additional 1,502,342 shares during the last quarter. Altshuler Shaham Ltd purchased a new stake in OPKO Health during the 4th quarter valued at about $2,082,000. Finally, Norges Bank acquired a new position in shares of OPKO Health in the 4th quarter valued at about $1,657,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Stock Up 2.4 %

OPKO Health stock opened at $1.72 on Tuesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The business’s 50-day simple moving average is $1.54 and its two-hundred day simple moving average is $1.55. The company has a market cap of $1.17 billion, a PE ratio of -9.05 and a beta of 1.63. OPKO Health has a fifty-two week low of $0.86 and a fifty-two week high of $1.76.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on OPK. Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th. StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Wednesday, January 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.